Diagnostic Biomarkers Market Report 2026

The diagnostic biomarkers market size has grown rapidly in recent years. It will grow from $75.46 billion in 2025 to $87.47 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to growth in molecular diagnostics, expansion of cancer research, limitations of traditional diagnostics, rising chronic disease burden, biomarker validation studies.

The diagnostic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $155.92 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to advancements in omics technologies, personalized medicine growth, ai-based biomarker discovery, regulatory approvals for novel biomarkers, demand for predictive diagnostics. Major trends in the forecast period include rising adoption of precision diagnostic biomarkers, increasing use of genomic and proteomic biomarkers, expansion of biomarkers in oncology diagnostics, integration of biomarker data with clinical analytics, growing demand for early disease detection.

The increasing prevalence of cancer is expected to drive the growth of the diagnostic biomarkers market in the coming years. The rise in cancer cases is influenced by factors such as aging populations, lifestyle changes, environmental exposure, and advancements in diagnostic techniques. Diagnostic biomarkers play a vital role in oncology by supporting early detection, accurate diagnosis, and personalized treatment approaches, thereby improving patient outcomes. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, cancer cases increased to 2,001,140 compared with 1,958,310 in 2023, representing a growth of 2.19%. Therefore, the rising prevalence of cancer is driving the expansion of the diagnostic biomarkers market.

Major companies operating in the diagnostic biomarkers market are concentrating on the development of non-invasive diagnostic approaches, such as blood-based biomarker tests, to improve patient comfort and expand access to personalized treatment strategies. Blood-based biomarker tests are diagnostic tools that analyze specific biological markers in blood samples to detect or monitor diseases in a minimally invasive manner. For instance, in July 2023, Quanterix Corporation, a US-based life sciences company, launched LucentAD, a blood-based biomarker test designed to support the diagnosis of Alzheimer’s disease in patients presenting early cognitive symptoms. The test measures plasma levels of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker linked to amyloid pathology in the brain and a key indicator of Alzheimer’s disease. By offering a less invasive and more accessible alternative to traditional diagnostic methods such as cerebrospinal fluid analysis or amyloid positron emission tomography, LucentAD aims to simplify and accelerate the diagnostic evaluation of suspected Alzheimer’s patients.

In September 2024, Trinity Biotech, an Ireland-based clinical diagnostics company, acquired Metabolomics Diagnostics for approximately $1.3 million. Through this acquisition, Trinity Biotech gains access to a mass spectrometry platform integrated with machine learning-based bioinformatics, strengthening its capabilities in biomarker-driven diagnostic solutions. Metabolomics Diagnostics is an Ireland-based company focused on developing innovative biomarker-based diagnostics for complex diseases.

Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS.

North America was the largest region in the diagnostic biomarkers market in 2025. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diagnostic biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diagnostic biomarkers market by increasing costs of imported reagents, assay kits, analytical instruments, and laboratory consumables. Diagnostic labs and research institutes in North America and Europe are most affected due to reliance on imported materials, while Asia-Pacific faces higher testing costs. These tariffs increase diagnostic expenses. However, they encourage local reagent manufacturing and domestic assay development.

The diagnostic biomarkers market research report is one of a series of new reports that provides diagnostic biomarkers market statistics, including diagnostic biomarkers industry global market size, regional shares, competitors with a diagnostic biomarkers market share, detailed diagnostic biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic biomarkers industry. This diagnostic biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A diagnostic biomarker is a biological indicator used to help identify and diagnose a disease, enabling differentiation from other conditions. It may include a wide range of measures such as laboratory test results, imaging findings, genetic indicators, and physiological changes, and can also offer insights into disease progression and the effectiveness of treatment.

The main product types in the diagnostic biomarkers market include safety biomarkers, efficacy biomarkers, and validation biomarkers. Safety biomarkers are measurable indicators used to evaluate the risk of toxicity or adverse effects related to medical treatments or environmental exposures, helping determine treatment safety by monitoring biological responses that may signal harm. Diagnostic biomarkers are applied across areas such as oncology, metabolic diseases, and neurological disorders, and are used by end users including hospitals, cancer research institutes, and diagnostic laboratories.

The diagnostic biomarkers market consists of revenues earned by entities by providing services such as biomarker assay development and validation, biomarker-based diagnostic testing services, clinical trial support services, and data management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diagnostic biomarkers market also includes sales of biomarker assays, liquid biopsy kits, digital biomarkers, and genetic testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.